title: Dramatis Personae in β-Cell Mass Regulation: Enter SerpinB1.
abstract: How is β-cell mass adjusted to changes in the functional insulin requirements? The answer to this question is central to the understanding of the causes and (potentially) the therapy of type 2 diabetes. In this issue of Cell Metabolism, El Ouaamari et al. (2016) report that increased production of the protease inhibitor SerpinB1 in the liver links insulin resistance to stimulation of β-cell proliferation.
authors.affiliation: Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Headington, OX3 7LE, Oxford, UK; Oxford National Institute for Health Research, Biomedical Research Centre, Churchill Hospital, Headington, OX3 7LE, Oxford, UK.
authors.forename: Andrei I
authors.initials: AI
authors.lastname: Tarasov
authors.affiliation: Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Headington, OX3 7LE, Oxford, UK; Oxford National Institute for Health Research, Biomedical Research Centre, Churchill Hospital, Headington, OX3 7LE, Oxford, UK; Department of Physiology, Institute of Neuroscience and Physiology, University of Goteborg, Box 432, S-40530 Göteborg, Sweden. Electronic address: patrik.rorsman@ocdem.ox.ac.uk.
authors.forename: Patrik
authors.initials: P
authors.lastname: Rorsman
mesh_terms: D003924:Diabetes Mellitus, Type 2; D006801:Humans; D007328:Insulin; D007333:Insulin Resistance; D050417:Insulin-Secreting Cells; D008099:Liver
chemical_list: D007328:Insulin